60 CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy-Reference-Cited by-同舟云学术

60 CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy

Published:2023-04 Issue:4 Volume:18 Page:S39-S40
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Neal J.,Pavlakis N.,Kim S-W.,Goto Y.,Lim S.M.,Mountzios G.,Fountzilas E.,Mochalova A.,Christoph D.C.C.,Bearz A.,Quantin X.,Palmero R.,Antic V.,Chun E.,Edubilli T. Rao,Lin Y-C.,Huseni M.,Scheffold C.,Vervaet P.,Newsom-Davis T.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions;Cancer Letters;2024-11

2. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study;Journal of Clinical Oncology;2024-08-20

3. New promises and challenges in the treatment of advanced non-small-cell lung cancer;The Lancet;2024-08

4. Systemic treatment options for non-small cell lung cancer after failure of previous immune checkpoint inhibitors: a bayesian network meta-analysis based on randomized controlled trials;BMC Immunology;2024-06-28

5. Beyond Chemoimmunotherapy in Advanced Non–Small Cell Lung Cancer: New Frontiers, New Challenges;American Society of Clinical Oncology Educational Book;2024-06